Loading company…
Phoska Biopharma develops therapies for liver and metabolic conditions.
Founded in 2019 and based in Singapore, Phoska Biopharma is a preclinical company developing therapies for liver and metabolic conditions, including fatty liver, and for cardiovascular health. In August 2022, it raised USD 1 million in venture funding from Albrekca and Sprim Ventures. Mark Hasleton was CEO as of August 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in